- US-listed companies
- Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc.NTLA
Market cap
$2.3B
P/E ratio
Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | |
Collaboration revenue | - | - | 30 | 43 | 58 | - | 52 |
Research and development | 32 | 68 | 89 | 108 | 150 | - | 420 |
General and administrative | 17 | 28 | 32 | 41 | 44 | - | 90 |
Total operating expenses | 49 | 96 | 121 | 149 | 195 | - | 510 |
Operating loss | -32 | -70 | -91 | -106 | -137 | - | -458 |
Interest income | 1 | 2 | 6 | 7 | 2 | - | 9 |
Loss from equity method investments | - | - | - | - | - | 1 | -11 |
Change in fair value of contingent consideration | - | - | - | - | - | - | 13 |
Total other (expense) income, net | - | - | - | - | - | - | -16 |
Net loss | -32 | -68 | -85 | -100 | -134 | -268 | -474 |
Net Loss Per Share, Basic | - | - | - | - | - | - | -6.16 |
Net Loss Per Share, Diluted | - | - | - | - | - | - | -6.16 |
Unrealized loss on marketable securities | - | - | -0 | 0 | -0 | - | -2 |
Other comprehensive loss from equity method investment | - | - | - | - | - | - | -3 |
Comprehensive loss | - | - | -85 | -99 | -134 | - | -479 |